HomeCompareSPPCF vs ABBV

SPPCF vs ABBV: Dividend Comparison 2026

SPPCF yields 6.47% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $73.9K in total portfolio value
10 years
SPPCF
SPPCF
● Live price
6.47%
Share price
$0.31
Annual div
$0.02
5Y div CAGR
0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.8K
Annual income
$999.92
Full SPPCF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — SPPCF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPPCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPPCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPPCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPPCF
Annual income on $10K today (after 15% tax)
$549.94/yr
After 10yr DRIP, annual income (after tax)
$849.93/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,016.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPPCF + ABBV for your $10,000?

SPPCF: 50%ABBV: 50%
100% ABBV50/50100% SPPCF
Portfolio after 10yr
$67.8K
Annual income
$13,362.82/yr
Blended yield
19.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SPPCF
No analyst data
Altman Z
6.4
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPPCF buys
0
ABBV buys
0
No recent congressional trades found for SPPCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPPCFABBV
Forward yield6.47%3.12%
Annual dividend / share$0.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.2%40.6%
Portfolio after 10y$30.8K$104.7K
Annual income after 10y$999.92$25,725.73
Total dividends collected$8.3K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPPCF vs ABBV ($10,000, DRIP)

YearSPPCF PortfolioSPPCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,348$648.28$11,559$438.51$211.00ABBV
2$12,832$688.93$13,494$640.86$662.00ABBV
3$14,459$729.47$15,951$945.97$1.5KABBV
4$16,241$769.77$19,152$1,413.89$2.9KABBV
5$18,188$809.68$23,443$2,146.38$5.3KABBV
6$20,310$849.10$29,391$3,321.96$9.1KABBV
7$22,620$887.92$37,948$5,265.87$15.3KABBV
8$25,129$926.05$50,795$8,596.74$25.7KABBV
9$27,851$963.40$71,034$14,549.41$43.2KABBV
10$30,801$999.92$104,715$25,725.73$73.9KABBV

SPPCF vs ABBV: Complete Analysis 2026

SPPCFStock

Steppe Cement Ltd., an investment holding company, produces and sells cement and clinkers in Kazakhstan. It also engages in the provision of consultancy services; and transmission and distribution of electricity. The company is headquartered in Kuala Lumpur, Malaysia.

Full SPPCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SPPCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPPCF vs SCHDSPPCF vs JEPISPPCF vs OSPPCF vs KOSPPCF vs MAINSPPCF vs JNJSPPCF vs MRKSPPCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.